SOUTH SAN FRANCISCO, Calif., Mar 02, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (Nasdaq:EXEL) announced the following upcoming investor events:

• Cowen 31^st Annual Health Care Conference: Michael Morrissey, PhD, the company's president and chief executive officer, will present at 1:20 p.m. EST / 10:20 a.m. PST on Tuesday, March 8, 2011, in Boston, Massachusetts.
• Barclays Capital 2011 Global Healthcare Conference: Dr. Morrissey will present at this conference at 4:45 p.m. EDT / 1:45 p.m. PDT on Tuesday, March 15, 2011, in Miami, Florida.

At each of these investor events, Dr. Morrissey will review the most recent publicly available data for cabozantinib (XL184) in castration-resistant prostate cancer (CRPC) and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. He will also discuss the company's financial outlook and provide a general business update.

Each of these investor events will be webcast and may be accessed on the Event Calendar page under Investors at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor Relations and Corporate Communications
cbutler@exelixis.com